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Summary
Background—Frontotemporal dementia (FTD) is a complex disorder characterised by a broad
range of clinical manifestations, differential pathological signatures, and genetic variability.
Mutations in three genes—MAPT, GRN, and C9orf72—have been associated with FTD. We
sought to identify novel genetic risk loci associated with the disorder.
Methods—We did a two-stage genome-wide association study on clinical FTD, analysing
samples from 3526 patients with FTD and 9402 healthy controls. All participants had European
ancestry. In the discovery phase (samples from 2154 patients with FTD and 4308 controls), we did
separate association analyses for each FTD subtype (behavioural variant FTD, semantic dementia,
progressive non-fluent aphasia, and FTD overlapping with motor neuron disease [FTD-MND]),
followed by a meta-analysis of the entire dataset. We carried forward replication of the novel
suggestive loci in an independent sample series (samples from 1372 patients and 5094 controls)
and then did joint phase and brain expression and methylation quantitative trait loci analyses for
the associated (p<5 × 10−8) and suggestive single-nucleotide polymorphisms.
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Findings—We identified novel associations exceeding the genome-wide significance threshold
(p<5 × 10−8) that encompassed the HLA locus at 6p21.3 in the entire cohort. We also identified a
potential novel locus at 11q14, encompassing RAB38/CTSC, for the behavioural FTD subtype.
Analysis of expression and methylation quantitative trait loci data suggested that these loci might
affect expression and methylation incis.
Interpretation—Our findings suggest that immune system processes (link to 6p21.3) and
possibly lysosomal and autophagy pathways (link to 11q14) are potentially involved in FTD. Our
findings need to be replicated to better define the association of the newly identified loci with
disease and possibly to shed light on the pathomechanisms contributing to FTD.
Funding—The National Institute of Neurological Disorders and Stroke and National Institute on
Aging, the Wellcome/ MRC Centre on Parkinson’s disease, Alzheimer’s Research UK, and Texas
Tech University Health Sciences Center.
Introduction
Frontotemporal dementia (FTD) is the second most common form of young-onset dementia
after Alzheimer’s disease and comprises about 10–20% of all dementias worldwide.1 FTD
occurs in roughly three to 15 per 100 000 individuals aged between 55 years and 65 year2
The disease has an insidious onset: it is familial in 30–50% of patients and affects men and
women almost equally.3 The main clinical syndromes are the behavioural variant1,4 and the
language variants (semantic dementia and progressive nonfluent aphasia).1,5 FTD also
overlap with motor neuron disease (FTD-MND), and atypical parkinsonian disorders.3 The
molecular pathology is heterogeneous and based on the type of neuronal lesions and protein
inclusions: 40% or more of patients have frontotemporal lobar degeneration (FTLD) with
tau pathology (FTLD-tau), about 50% have TDP-43 (TAR DNA-binding protein 43)
pathology (FTLD-TDP),6 and the remaining 10% have inclusions positive for fused in
sarcoma (FUS; FTLD-FUS) or ubiquitin/p62 (FTLD-UPS [ubiquitin proteasome system]).7
Mutations in three main genes are commonly associated with FTD: the microtubule-
associated protein tau (MAPT),8 granulin (GRN),9,10 and C9orf72.11–15 Mutations in the
charged multivesicular body protein 2B (CHMP2B), the valosin-containing protein (VCP),
and ubiquilin 2 (UBQLN2) genes are rare causes of disease.13,16 Findings from a previous
genome-wide association study (GWAS) of neuropathologically confirmed FTLD-TDP (515
patients vs 2509) showed TMEM106B to be a disease risk factor.17
We did a larger GWAS in samples from people with clinical FTD, and we report results for
the discovery, replication, and joint phase analyses, as well as for assessment of the effect on
expression and methylation quantitative trait loci (QTL) exerted by associated or suggestive
SNPs. We aimed to identify novel genetic risk loci associated with FTD and its subtypes.
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Methods
Study population
44 international research groups (appendix) contributed samples to this two-stage (discovery
phase and replication phase) GWAS of clinical FTD. Investigators at every site obtained
appropriate written informed consent from patients and control individuals. Every
participating group provided consent for the use of these samples for the purposes of this
study. The patients included in the discovery phase were diagnosed according to the Neary
criteria1 for FTD, whereas those included in replication phase were diagnosed according to
the Neary criteria,1 or the revised criteria for behavioural FTD4 and the language variants of
FTD5 at every collaborative site. For each patient, the diagnosis was made by a neurologist
with an interest in FTD or (the minority: <5%) by pathological diagnosis. To cover the most
relevant FTD clinical signatures, we included patients diagnosed with behavioural FTD,
semantic dementia, progressive nonfluent aphasia, or FTD-MND.18 We reviewed all
patients with a diagnosis of language impairment to exclude cases of the logopenic variant
of primary progressive aphasia,5 most of which are associated with Alzheimer’s disease
pathology. Samples were obtained from North America (USA and Canada), UK, France, the
Netherlands, Belgium, Germany, Denmark, Sweden, Spain, and Italy and all patients were
of confirmed European ancestry.
DNA was collected at the three institutions leading this project: the Department of
Molecular Neuroscience at University College London (UCL), UK; the Laboratory of
Neurogenetics of the National Institute on Aging at the National Institutes of Health (NIH),
MD, USA; and the Laboratory of Neurogenetics at the Texas Tech University Health
Sciences Center (TTUHSC); TX, USA. All samples were anonymous and stored with a
patientspecific coded identification number. Each DNA sample was assessed for quality
with gel electrophoresis and DNA concentrations were assessed via spectrophotometer
(Nanodrop; Wilmington, DE, USA) or fluorometer (Qubit; Life Technologies, Grand Island,
NY, USA). Samples from non-overlapping patients were genotyped at the Laboratory of
Neurogenetics of the National Institute on Aging, NIH (40%) or at the core facility at the
Institute of Child Health, UCL (60%). We obtained standardised clinical, pathological, and
genetic data for each patient from all the collaborating groups (appendix). Sporadic cases
along with probands from FTD families were included in the study.. We excluded carriers of
mutations in MAPT and GRN. We did not exclude individuals with C9orf72 expansions
because this locus was identified subsequent to sample collection. After quality control of
genotyping data and detailed assessment of the clinical diagnosis, we used 2154 and 1372
samples in the discovery phase and replication phase, respectively, for association analysis
(table 1). In total, after quality control, we analysed 3526 FTD samples (table 1). Further
details about cases included in the study are provided in the appendix.
Control samples for the discovery phase were taken from studies previously done at the
Laboratory of Neurogenetics of the National Institute on Aging at the NIH or at UCL.
Control individuals were matched to patients on the basis of population ancestry and
See Online for appendix
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genotyping platform. Aggregate data for control samples were merged based on overlapping
single-nucleotide polymorphisms (SNPs). The selected 7444 control samples were from the
USA, UK, Italy, Germany, France, Sweden, and the Netherlands, and were used as controls
in previous GWAS;19 all individuals had given consent for their samples to be used as
controls. All were free of neurological illness at the time of sampling, but most had not been
screened for the absence of a family history of FTD. For each patient, at least two controls
were matched based on compatibility of genetic ancestry estimates by principal components
analysis to accommodate the lack of precisely matched clinical controls. After quality
control, we included 4308 control samples in this study. The genotyping of controls for the
replication phase was done at the Laboratory of Neurogenetics of the National Institute on
Aging, NIH (90%) and at the core facility at the Institute of Child Health, UCL (10%). All
control samples used in the replication phase were collected from the groups participating in
the study (5094 samples passed quality control) and were of European ancestry from the
following countries: USA (European American), UK, Italy, France, Germany, Sweden,
Spain, and the Netherlands.
Procedures
For every sample, 2 µg of DNA extracted from either blood or the brain at each
collaborative site was collected (whole genome amplified DNA samples were excluded).
Samples were securely stored at −20°C. Every sample was first screened for integrity and
purity by means of gel electrophoresis on 1% agarose gel, and concentrations were analysed
by spectrophotometric (Nanodrop) or fluorometric (Qubit) quantification. The same
procedure was implemented at NIH, UCL, and TTUHSC.
Samples from patients and control individuals included in the discovery phase were
genotyped using Illumina human 370K, 550K, and 660K Quad Beadchips and Omni
Express chips (Illumina Inc, CA, USA). We used Illumina NeuroX custom chips for all
samples included in replication phase genotyping. The NeuroX chip is a partially custom-
designed chip that specifically targets the main loci associated with several different
neurological disorders obtained from GWAS or whole-exome sequencing data. The NeuroX
chip holds about 267K SNPs, of which 3759 were FTD-specific, being selected from SNPs
that had p values of less than 1 × 10−4 during the discovery phase of the study. These SNPs
were tag SNPs based on European ancestry linkage-disequilibrium patterns from the most
up-to-date data for samples of European ancestry from the 1000 Genomes project.20 For all
GWAS significant hits and candidate SNPs, five linkage-disequilibrium-based proxies or
technical replicates were included on the array per locus, tagging associations within +/−250
kb and r2 >0·5 from the most strongly associated proximal SNP. To replicate each locus, we
picked the tag SNP most significant in the discovery phase before beginning. If no linkage-
disequilibrium-based proxies were available, technical replicates were included. All
genotyping arrays (discovery phase and replication phase) were assayed on the Illumina
Infinium platform (Illumina, San Diego, CA, USA) at the Laboratory of Neurogenetics of
the National Institute on Aging, NIH and at the core facility at the Institute of Child Health,
UCL. All genotypes for this project were called centrally using Illumina Genome Studio and
all 3759 SNPs of interest for FTD were manually examined to ensure high-quality genotype
clusters before data export.
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For the purpose of assessing possible biological relevance for any associated SNPs we used
quantitative trait loci (QTL) data generated by the UK Brain Expression Consortium
(UKBEC) and the North American Brain Expression Consortium (NABEC) for brain tissues
assayed for genome-wide expression and methylation. Details about sample collection,
RNA/DNA extraction, and genotyping are provided in the appendix.
Statistical analysis
We did standard quality control for GWAS data before association analyses. Briefly, for the
discovery phase, we extracted overlapping SNPs across all Illumina arrays used. This was
done as a means of dealing with the low numbers of matched cases and controls per study
site or chip type to facilitate the FTD subtype analyses. We maximised sample size for the
subtype analyses by pooling as many possible samples while sacrificing some array content,
leaving 228 189 autosomal SNPs as a basis for imputation after the quality control was
completed. We excluded samples possibly mismatched for sex by assessing X chromosome
heterozygosity. Samples with a call rate of greater than 95% and SNPs with a minor allele
frequency greater than 1% were filtered and included in the analyses. We calculated Hardy-
Weinberg equilibrium p values (exclusion at p values <1 × 10−5). We assessed non-random
missingness per SNP by case-control status with exclusion at p values of less than 1 × 10−5
and non-random missingness per SNP by haplotype at p values for exclusion <1 × 10−5. We
assessed the presence of relatedness by identifying and excluding first-degree relatives
(through identity by descent for any pairwise with an estimate of less than 0·125) and
verified European ancestry by principal components analysis compared with HapMap3
populations, with European ancestry ascertained at values for the first two eigenvectors less
than six SDs from the population mean for the combined Europeans from Utah and Tuscans
from Italy reference samples.21 After preliminary quality assessment, principal components
analysis as implemented in EIGENSTRAT22 was used to assess matching between cases
and controls based on all available cases and controls. Custom coding in R was used to
match cases to controls. We treated each subtype (behavioural FTD, semantic dementia,
progressive nonfluent aphasia, and FTD-MND) as a separate group in which the two most
genetically similar unique controls per case were selected based on eigenvectors 1 and 2 in
order to compensate for a lack of precisely matched controls at recruitment. In this respect,
matched controls were unique per case and non-redundant across subtype datasets. Thus,
cases and controls were matched for each subtype (behavioural FTD, semantic dementia,
progressive nonfluent aphasia, and FTD-MND) based on similarity of the first two
eigenvectors from principal components analysis and did not overlap across subtypes. We
used logistic regression based on imputed dosages to assess the association between each
SNP and any of the FTD subtypes, adjusting for eigenvectors 1 and 2 from principal
components analysis as covariates. Eigenvectors were generated separately for each subtype,
as in the overall sample pool, parameter estimates for the first two were associated with case
status at p values of less than 0·05. We did fixed-effects meta-analyses to combine results
across subtypes and quantify heterogeneity across subtypes. Genomic inflation was minimal
across subtypes and in the meta analysis across subtypes (λ<1·05), therefore we did not use
genomic control (see appendix for quantile-quantile plots and λ values per discovery phase
analysis). SNPs were imputed to August, 2010 release of the 1000 Genomes haplotypes
using default settings of minimac and were excluded if their minor allele frequency was less
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than 0·01 or imputation quality (Rsq) was less than 0·30 across all samples, leaving 6 026
385 SNPs for analyses.
For the replication phase, we did standard quality control as for the discovery phase with
slight adjustments to account for the bias in NeuroX array content (candidate neurological or
neurodegenerative disease SNPs and exonic content). Standard content variants included on
the NeuroX array that were used for sample quality control were called using a publicly
available cluster file based on more than 60 000 samples.23 For quality control, variants with
GenTrain scores greater than 0·70 (indicative of high-quality genotype clusters) were
extracted first to calculate call rates. Samples with call rates greater than 95% were
excluded, as were samples whose genetically determined sex conflicted with that from the
clinical data and samples exhibiting excess heterozygosity. Next, SNPs overlapping with
HapMap phase 3 samples were extracted from the previous subset and pruned for linkage
disequilibrium (SNPs excluded if r2 >0·50 within a 50 SNP sliding window), and SNPs with
minor allele frequency less than 5%, Hardy-Weinberg equilibrium p values less than 1 ×
10−5, and per SNP missingness rates greater than 5%. At this stage, we used pairwise
identity-by-descent filtering to remove samples that were cryptically related and principal
components analysis to identify samples to be excluded when genetic ancestry was not
consistent with European descent based on comparisons with HapMap phase 3 reference
populations. For replication analyses and due to an effort to maximise the restricted power
of this phase compared to the discovery phase, analyses of each subtype included all control
samples available, adjusting for the first five eigenvectors only from principal components
analysis as covariates in the logistic regression model. No other adjustments were
implemented. Additionally, we pooled the individual genotypes from different subsets in the
replication phase to help increase statistical power. For details about QTL statistical
analysis, see appendix.
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data
interpretation, or writing of the report. No pharmaceutical company or other agency paid to
write this article. The corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
Results
In the discovery phase, we analysed samples from 2154 patients (table 1) and 4308 controls.
We first did separate association analyses for each subtype (behavioural FTD, semantic
dementia, progressive nonfluent aphasia, and FTD-MND; table 2) and then undertook a
meta-analysis of the entire dataset. Findings from the meta-analysis showed 29 SNPs
(appendix) exceeding genome-wide significance (p value <5×10−8) at the HLA locus
(6p21.3), encompassing the butyrophilinlike 2 (MHC class II associated) gene (BTNL2) and
the major histocompatibility complex, class II, DR alpha (HLA-DRA), and DR beta 5 (HLA-
DRB5; figure, table 3). To identify susceptibility loci for the behavioural FTD subtype we
analysed 1377 patient samples (table 2) and 2754 control samples. Two non-coding SNPs at
11q14, locating to intron 1 of the gene RAB38, member RAS oncogene family (RAB38;
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rs302652) and encompassing RAB38 and cathepsin C (CTSC; rs74977128), passed the
genome-wide significance threshold (figure, table 3). Similarly, we did analyses on the other
subtypes (table 1): 308 semantic dementia versus 616 controls, 269 progressive nonfluent
aphasia versus 538 controls, and 200 FTD-MND versus 400 controls. No SNP reached
genome-wide significance in either subtype, probably due to the small sample size.
However, several SNPs (appendix) showed suggestive associations (p values between 1 ×
10−6 and 1 × 10−7; figure) and warrant further investigation in future screenings.
In the replication phase, we analysed samples from 1372 patients (table 1) and 5094
controls. We assessed the associated SNPs at 6p21.3 (rs9268877, rs9268856, and
rs1980493) in the whole replication cohort (table 3). Table 3 shows findings from the
surrogate or proxy SNPs assessed for replication at 11q14 in 690 behavioural FTD cases:
rs302668 and rs16913634. Combined analyses of discovery and replication phases showed
genome-wide significant association at 6p21.3 for all SNPs (table 3). Joint p values of the
SNPs at 11q14 only revealed suggestive association for rs302668 (table 3) possibly because
of decreased power due to proxy-based replication (r2 of rs302652 to rs302668=0·65).
We then assessed biological relevance for the novel potential loci in human brain cortex
tissues assayed for genome-wide expression and methylation. There was no eQTL in our
dataset, but assessment of Zeller and colleagues’ dataset38 showed a cis-eQTL (p=5·05 ×
10−32; appendix) at 11q14 for rs302652 (chr11:87894881, risk allele T) causing a decreased
expression of RAB38 (Illumina ILMN_2134974 located on chr11:87846656-87846705) in
monocytes. These data suggest a role in transcriptional processes in cis for this SNP.
Furthermore, we identified significant cis-mQTL at 6p21.3 after multiple test correction for
rs1980493 (risk allele T) that associated with changes in the methylation levels related to
HLADRA in the frontal cortex (table 4).
To assess potential genetic overlap between FTD and closely related forms of
neurodegenerative diseases we selected relevant SNPs for candidate loci and analysed them
in our dataset. This analysis included published association studies for amyotrophic lateral
sclerosis,39 progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD),40
Alzheimer’s disease,41 and FTLD-TDP.17 We also assessed whether the two loci identified
through this study had also been reported previously in other studies of neurological
disorders.
For the C9orf72 locus (for amyotrophic lateral sclerosis), the SNP rs3849942 (effect allele
A) was associated with the FTD-MND subtype, which was consistent with our post-hoc
analyses (about 23% of expansion carriers in this subtype; table 5; appendix). Association
was modest in behavioural FTD (p=7·38×10−3, OR=1·155) as well as in the entire discovery
cohort, but we saw no evidence for association in the semantic dementia or progressive
nonfluent aphasia subtypes (table 5). These results confirm that the C9orf72 locus associates
mainly with FTD-MND and to a lesser extent with behavioural FTD (appendix).
For the MAPT locus (PSP/CBD), the SNPs rs242557 (effect allele G) and rs8070723 (effect
allele A)40 were significantly associated only within the entire cohort and in the behavioural
FTD and progressive nonfluent aphasia subtypes (rs8070723 only; table 5). The effect was
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small in our study although in the same direction as in the GWAS for progressive
supranuclear palsy (5·4640 vs about 1·2–1·4 in our study; table 5). These results might have
arisen because we excluded all known chromosome 17 mutation carriers and because tau
pathology is a less common feature of sporadic FTD.
For the TOMM40/APOE locus (Alzheimer’s disease), the SNP rs2075650 (effect allele G)
(table 5). Several Alzheimer’s disease GWASs reported association with the minor allele of
this SNP with ORs greater than 2·5,41 but in our study the OR was about 1·3 (table 5). This
suggestive association might be indicative of clinical overlap between patients with
clinically diagnosed FTD and those with Alzheimer’s disease.42
For the TMEM106B locus (FTLD-TDP), we assessed the three associated SNPs reported by
Van Deerlin and colleagues (rs1990622, effect allele A; rs6966915, effect allele C;
rs1020004, effect allele T).17 All achieved modest p values in the entire dataset with lowest
p values in the range of 10−2–10−3 only in the behavioural FTD subtype (table 5). Van
Deerlin and colleagues’ study17 was done on samples from patients with autopsy-confirmed
FTLD-TDP, whereas our cohort is mainly clinically defined. Additionally, the previous
study included many GRN mutation carriers, who frequently present with behavioural
FTD;17 in our study, GRN mutation carriers were excluded. Biochemical evidence has
suggested that TMEM106B is directly related to GRN metabolism,13 thus we regard our data
as a limited replication of the original finding.
Finally, the RAB38 locus previously showed suggestive association in multiple sclerosis,43
but the HLA locus was reported to associate with multiple sclerosis,44,45 Parkinson’s
disease,19,46 and Alzheimer’s disease.47 None of the SNPs reported in these studies, and
which were assessed in our dataset (table 5),43–46 showed association with FTD, probably
suggesting that different risk haplotype sub-structures at the same loci associate with
distinctive phenotypes.
Discussion
FTD is characterised by a broad range of clinical manifestations, differential pathological
signatures, and substantial genetic variability, which imply a complex disease
mechanisms.15 In the search for novel disease risk loci associated with FTD we have done
an extensive GWAS on a large cohort of mainly clinically diagnosed FTD samples from
patients of European ancestry. Several limitations might apply to this study. In view of the
phenotype heterogeneity of FTD, and considering that it is a rare neurodegenerative
disorder,2 testing the hypothesis “common variant – common disease” for diseases of this
kind is challenging and clearly benefits from large sample sizes. Additionally, our findings
might indicate association with specific loci without necessarily implying causality; low
heritability due to common variability can also apply. However, the QQ plots and associated
λ values (appendix) conformed to GWAS standards, lending support to our findings.
We included samples from more than 3500 patients and, thus, we know of no larger GWAS
for FTD. We have identified two novel potential loci for FTD: 11q14, encompassing
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RAB38/CTSC, was suggestive for the behavioural FTD subtype, and 6p21.3, encompassing
the HLA locus was statistically significant for the entire cohort.
RAB3848 encodes the transmembrane protein RAB38, which is expressed in the thyroid, in
elements of the immune system, and in the brain. From a functional perspective, RAB38 has
been shown to mediate protein trafficking to lysosomal-related organelles and maturation of
phagosomes (panel).49,50 CTSC is a lysosomal cysteine-proteinase that participates in the
activation of serine proteinases in immune and inflammatory cells that are involved in
immune and inflammatory processes including phagocytosis of pathogens and local
activation and deactivation of inflammatory factors (Online Mendelian Inheritance in Man
[OMIM] number 602365). The SNP rs302652 at the RAB38/CTSC locus shows an eQTL in
monocytes38 associated with decreased expression of RAB38, possibly indicating that a
decreased function of RAB38 might be the mechanism by which the association at this locus
is mediated. Both RAB38 and CTSC are implicated in lysosomal biology and an association
with lysosomal and autophagic processes in FTD was previously suggested in two studies of
GRN51 and TMEM106B.52 A role for autophagy has also been shown in Parkinson’s
disease.53 Our findings will need to be replicated in other FTD cohorts in follow-up studies
(eg, fine-mapping studies) to lend support to the proposal that lysosomal biology and
autophagy might be involved in the aetiology of FTD.54
The genetic association that we identified with the HLA locus supports the idea of a link
between FTD and the immune system. Our mQTL data showed that risk at this locus is
associated with cis-changes in methylation levels of HLA-DRA in the frontal cortex. HLA
associations have been previously reported in Alzheimer’s disease,47 Parkinson’s
disease,19,46 and multiple sclerosis.44,45 Additionally, a general involvement of the innate
and the adaptive immune responses has been suggested in the pathogenesis of
neurodegenerative diseases,55,56 lending supporting to the idea that the immune system
plays an important part within the spectrum of neurological disorders.
Future studies should aim to replicate our findings and, in so doing, elucidate the functional
basis of FTD. Additionally, our data indicate that common pathways and processes might
underlie different forms of neurodegenerative disorders, including Alzheimer’s disease,
Parkinson’s disease, multiple sclerosis, and FTD. Exploring the possibility of developing
therapeutic measures targeting general damage responses could hold promise—after
replication and validation of our findings—for the development and implementation of
treatment options for these neurological disorders, including FTD.
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Panel: Research in context
Systematic review
We searched PubMed for the most relevant research articles and review articles on
frontotemporal dementia using the following terms: “FTD” and “genetics”, and “FTD”
and “review”.1,4,5,8–17,54 We compared our results to several previously published
genome-wide association studies. We identified only one directly relevant study that
investigated a pathologically defined subtype of frontotemporal dementia (frontotemporal
lobar degeneration with TDP43-positive inclusions; FTLD-TDP).17 The other studies
were of related diseases such as amyotrophic lateral sclerosis,39 Alzheimer’s disease,41,47
progressive supranuclear palsy and corticobasal degeneration,40 multiple sclerosis,43–45
and Parkinson’s disease.19,46
Interpretation
To the best of our knowledge, ours is the first genome-wide association study in samples
from patients with clinical frontotemporal dementia. In view of the complexity and
heterogeneity of the disease, mutations in only three main genes—MAPT, GRN, and
C9orf72—have been associated with frontotemporal dementia, and these explain only a
small proportion of cases. Most importantly, little is known about the mechanisms
involved in the development of this disorder. Our findings suggest that common
variability in loci that point to immune processes, and possibly to lysosomal biology and
autophagy, are involved in the pathobiology of the disease. These findings provide a
basis for future replication and functional studies.
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Figure 1. Manhattan plots identifying regions with genome–wide significant associations
(A) Manhattan plot for the entire dataset of the discovery phase depicts the associated
regionat 6p21.3. Single–nucleotide polymorphisms (SNPs) with smallest p values and their
location within or in proximity of the nearest genes are shown. (B) Manhattan plot for the
behavioural frontotemporal dementia set in the discovery phase depicts the associated region
at 11q14.
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Figure 2. Manhattan plots identifying regions with genome–wide significant associations
SNPs with smallest p values and their location within or in proximity of the nearest genes
are shown.Manhattan plots for semantic dementia (C), progressive nonfluent aphasia (D),
and motor neurone disease (E) frontotemporal dementia sets.
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